

Table 1 : Demographics and Clinical Characteristics of Patients with COVID-19

	Total (N=2,954)	Mild/Moderate (N=1,439)	Severe/Critical (N=1,515)	P-value
Characteristics				
Age (yr.) – median (IQR)	60(50-68)	57(45-65)	63(54-71)	<0.001
Sex– no. (%)	-	-	-	1
Male	1,493(50.5%)	728(50.6%)	765(50.5%)	
Female	1,461(49.5%)	711(49.4%)	750(49.5%)	
Initial temperature (°C) – median (IQR)	-	-	-	0.002
≤37.3– no. (%)	2,833(95.9%)	1,398(97%)	1,435(94.7%)	-
37.3-38– no. (%)	85(2.9%)	25(2%)	60(4%)	-
38 -39– no. (%)	35(1.17%)	16(1%)	19(1.2%)	-
>39– no. (%)	1(0.03%)	0(0%)	1(0.1%)	-
Comorbidities – no. (%)				
Hypertension	889 (30%)	348 (24%)	541 (36%)	<0.001
Diabetes	401 (14%)	159 (11%)	242 (16%)	<0.001
Cardiovascular disease	330 (11%)	104 (7%)	226 (15%)	<0.001
Cerebrovascular disease	118 (4%)	34 (2%)	84 (6%)	<0.001
Cancer	74 (3%)	19 (1%)	55 (4%)	<0.001
Chronic obstructive pulmonary disease	139 (5%)	40 (3%)	99 (7%)	<0.001
Chronic renal disease	47 (2%)	14 (1%)	33 (2%)	0.012
Chronic liver disease	76 (3%)	36 (3%)	40 (3%)	0.817
Immunodeficiency	9 (0%)	4 (0%)	5 (0%)	1
Respiratory rate– median (IQR)	-	-	-	<0.001
>24 breaths per min– no. (%)	132(4%)	14(1%)	118(8%)	-
≤24 breaths per min–no. (%)	2,820(95%)	1,425(99%)	1,395(92%)	-
Hospital stays – median (IQR)	13(8-19)	12(8-17)	14(8-22)	<0.001
Death – no. (%)	59(2%)	0(0%)	59(4%)	<0.001
Clinical symptoms – no. (%)				
Fever	2,149 (73%)	1,032 (72%)	1,117 (74%)	0.231
Cough	2,062 (70%)	992 (69%)	1,070 (71%)	0.336
Shortness of breath	1302 (44%)	608 (42%)	694 (46%)	0.05
Chest Congestion	1,137 (38%)	517 (36%)	620 (41%)	0.006
Fatigue	669 (23%)	279 (19%)	390 (26%)	<0.001
Muscle soreness	118 (4%)	29 (2%)	89 (6%)	<0.001
Headache	17 (1%)	13 (1%)	4 (0%)	0.027
Dizziness	26 (1%)	14 (1%)	12 (1%)	0.695
Nausea	22 (1%)	12 (1%)	10 (1%)	0.671
Vomiting	22 (1%)	11 (1%)	11 (1%)	1

Diarrhea	64 (2%)	34 (2%)	30 (2%)	0.528
Radiological findings (N=2,567)– no. (%)				
Fuzzy boundary	304 (12%)	118 (9.6%)	186 (14%)	<0.001
Lymph node enlargement	30 (1.2%)	18 (1.5%)	12 (0.9%)	0.202
Ground glass opacity	2324 (91%)	1109 (90%)	1215 (91%)	0.304
Cystic change	209 (8.2%)	81 (6.6%)	128 (9.6%)	0.006
Airway obstruction	4 (0.16%)	2 (0.16%)	2 (0.15%)	1
Consolidation	332 (13%)	115 (9.4%)	217 (16%)	<0.001
Fine reticular opacity	56 (2.2%)	17 (1.4%)	39 (2.9%)	0.01
Lung texture increase	1529 (60%)	734 (60%)	795 (60%)	0.968
Intralobular septal thickening	14 (0.55%)	4 (0.33%)	10 (0.75%)	0.183
Pleural thickening	221 (8.6%)	72 (5.9%)	149 (11%)	<0.001
Pleural effusion	205 (8%)	34 (2.8%)	171 (13%)	<0.001
Bronchiectasis	53 (2.1%)	17 (1.4%)	36 (2.7%)	0.025
Viral load of throat swabs (N=1476) – median (IQR)				
ORF1ab	37.7 (34.51-40.08)	37.85 (34.85-40.05)	37.62 (34.07-40.15)	0.258
N	36.33 (33.77-37.82)	36.4 (34.08-37.77)	36.28 (33.5-37.91)	0.762
Anti-SARS-Cov-2 IgG and IgM level – median (IQR)				
IgG level	139.49 (73.93-181.24)	141.33 (74.82-180.45)	137.64 (73.88-181.45)	0.864
IgM level	26.88 (8.38-66.74)	26.46 (8.13-62.5)	27.32 (8.52-68.62)	0.337